

Pharmaceutical Treatments for Mental Health Disorders: Global Markets

https://marketpublishers.com/r/P409F51099F0EN.html

Date: February 2021

Pages: 128

Price: US\$ 2,750.00 (Single User License)

ID: P409F51099F0EN

Abstracts

Report Scope:

This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms.

Report Includes:

46 data tables and 12 additional tables

An overview of the global markets for pharmaceutical treatments for mental health disorders

Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025

Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth

Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COIVD-19 pandemic, social distancing and social isolation on the mental health conditions



A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19

Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)

Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders

Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders

Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies

Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles including, Eli Lilly, Johnson & Johnson, Pfizer, Takeda, and Shionogi



Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 DEPRESSION AND ANXIETY

Market Landscape

Segmentation by Drug Class

Segmentation by Company

Prevalence of Disorders

Diagnosis

Current Treatments

Selective Serotonin Reuptake Inhibitors (SSRIs)

Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)

Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)

Tricyclic Antidepressants (TCAs)

Monoamine Oxidase Inhibitors (MAOIs)

Atypical Antipsychotics and Second-Generation Antipsychotics (SGAs)

Benzodiazepines

Recent Drug Developments

Drug/Company

Late-Stage Drug Failures/Withdrawals

Drugs in Clinical Development to Treat Depression

Phase 3 Drugs in Development to Treat Depression

Phase 2 Drugs in Development to Treat Depression

Drugs in Clinical Development to Treat Anxiety

Phase 3 Drugs in Development to Treat Anxiety



Phase 2 Drugs in Development to Treat Anxiety
Alternative Approaches
Digital Therapeutics
M&A Activity
Future Opportunities

CHAPTER 4 ATTENTION DEFICIT HYPERACTIVITY DISORDER

Market Landscape

Segmentation by Geography

Segmentation by Drug Class

Segmentation by Company

Prevalence

Diagnosis

Current Treatments

Recent Drug Developments

Drugs/Companies

Late-Stage Drug Failures/Withdrawals

Drugs in Clinical Development to Treat ADHD

Phase 3 Drugs in Development to Treat ADHD

Phase 2 Drugs in Development to Treat ADHD

Alternative Approaches

Digital Therapeutics

M&A Activity

Future Opportunities

CHAPTER 5 SCHIZOPHRENIA

Market Landscape

Segmentation by Geography

Segmentation by Drug Class

Segmentation by Company

Prevalence

Diagnosis

Current Treatments

Recent Drug Developments

Drugs/Companies

Late-Stage Drug Failures/Withdrawals

Drugs in Clinical Development to Treat Schizophrenia



Phase 3 Drugs in Development to Treat Schizophrenia Phase 2 Drugs in Development to Treat Schizophrenia Alternative Approaches Digital Therapeutics M&A Activity Future Opportunities

CHAPTER 6 SUBSTANCE USE DISORDERS

Market Landscape

Segmentation by Geography

Segmentation by Drug Class

Segmentation by Company

Prevalence

Diagnosis

Current Treatments

Opioid Use Disorders

Alcohol Use Disorders

Nicotine Use Disorders

Recent Drug Developments

Drugs in Clinical Development to Substance Abuse Disorder

Phase 3 Drugs in Development to Treat Substance Use Disorders

Phase 2 Drugs in Development to Treat Substance Use Disorder

Alternative Approaches

Digital Therapeutics

M&A Activity

Future Opportunities

CHAPTER 7 COMPANY PROFILES

Pharmaceutical Companies

ABBVIE

ALKERMES PLC

ASTRAZENECA PLC

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ELI LILLY & CO.

GLAXOSMITHKLINE PLC

H LUNDBECK A/S

JOHNSON & JOHNSON



OTSUKA HOLDINGS CO. LTD.

PFIZER INC.

SHIONOGI & CO. LTD.

TAKEDA PHARMACEUTICALS CO. LTD.

Specialty Pharma and Biotechs

ACADIA PHARMACEUTICALS INC.

ADAMIS PHARMACEUTICALS CORP.

BIOXCEL THERAPEUTICS INC.

INTRA-CELLULAR THERAPIES INC.

INTERVEXION THERAPEUTICS

IRONSHORE PHARMACEUTICALS

KEMPHARM INC.

MINERVA NEUROSCIENCES INC.

NEOS THERAPEUTICS INC.

NLS PHARMACEUTICAL AG

NOVEN PHARMACEUTICALS INC.

SAGE THERAPEUTICS

SUPERNUS PHARMACEUTICALS, INC.

TONIX PHARMACEUTICALS HOLDINGS CORP.

TRIS PHARMA INC.

Digital Therapeutic Companies

OREXO AB

PEAR THERAPEUTICS



List Of Tables

LIST OF TABLES

Summary Table: Global Market for Drugs Prescribed to Treat Mental Health Disorders, by Type of Disorder, Through 2025

Table 1: Drugs in Phase 3 Development for Selected Psychiatric Disorders

Table 2: Global Market for Drugs Prescribed to Treat Depression and Anxiety, Through 2025

Table 3: Global Market for Brand Name Drugs Prescribed to Treat Depression and

Anxiety, by Leading Drug/Company, Through 2025

Table 4: Global Market for Drugs Prescribed to Treat Depression and Anxiety, by

Leading Company/Manufacturer

Table 5: Drug Profiles of Leading Approved Antidepressants

Table 6: Drugs Recommended for the Treatment of Anxiety

Table 7: Drugs in Clinical Development to Treat Depression

Table 8: Global Market for New Drugs Prescribed to Treat Depression, by

Drug/Company, Through 2025

Table 9: Drugs in Clinical Development to Treat Anxiety Disorders

Table 10: Global Market for New Brand Name Drugs Prescribed to Treat Anxiety, by Drug/Company

Table 11: Global Market for Digital Therapeutics, by Drug/Company, Through 2025

Table 12: Digital Therapeutics in Clinical Development for CNS Disorders

Table 13: Global Market for Drugs Prescribed to Treat Depression and Anxiety, Through 2025

Table 14: Global Market for Drugs Prescribed to Treat ADHD, Through 2025

Table 15: Global Market for Drugs Prescribed to Treat ADHD, by Region, Through 2025

Table 16: Global Market for Leading Brand Name Drugs Prescribed to Treat ADHD, by

Drug/Company, Through 2025

Table 17: Global Market for Drugs Prescribed to Treat ADHD, by Leading

Company/Manufacturer, Through 2025

Table 18: Drug Profiles of Leading Approved ADHD Treatments

Table 19: ADHD Drug Profiles

Table 20: Drugs in Clinical Development to Treat ADHD

Table 21: Global Market for New Drugs Prescribed to Treat ADHD, by Drug/Company,

Through 2025

Table 22: Global Market for Digital Therapeutics, Through 2025

Table 23: Global Market for Drugs Prescribed to Treat ADHD, Through 2025

Table 24: Global Market for Drugs Prescribed to Treat Schizophrenia, Through 2025



Table 25: Global Market for Drugs Prescribed to Treat Schizophrenia, by Region, Through 2025

Table 26: Global Market for Leading Brand Name Drugs Prescribed to Treat

Schizophrenia, by Drug/Company, Through 2025

Table 27: Global Market for Drugs Prescribed to Treat Schizophrenia, by Leading Company, Through 2025

Table 28: Drugs in Clinical Development to Treat Schizophrenia

Table 29: Drugs in Clinical Development to Treat Bipolar Disorder

Table 30: Global Market for New Drugs Prescribed to Treat Schizophrenia, Through 2025

Table 31: Global Market for Digital Therapeutics to Treat Schizophrenia, Through 2025

Table 32: Global Market for Drugs Prescribed to Treat Schizophrenia, Through 2025

Table 33: Global Market for Drugs Prescribed to Treat Substance Use Disorders,

Through 2025

Table 34: Global Market for Drugs Prescribed to treat Substance Use Disorders, by Region, Through 2025

Table 35: Global Market for Leading Brand Name Drugs Prescribed to Treat Substance Use Disorders, by Drug/Company, Through 2025

Table 36: Global Market for Drugs Prescribed to Treat Substance Use Disorders, by Leading Company, Through 2025

Table 37: Prevalence of Substance Use Disorders across the Globe, by Economy, 1990 vs. 2017

Table 38: Drugs in Clinical Development to Treat Substance Use Disorder

Table 39: Global Market for New Drugs to Treat Substance Abuse Disorders, by Drug/Company Through 2025

Table 40: Global Market for Digital Therapeutics, by Drug/Company, 2019-2025

Table 41: Global Market for Drugs Precribed to Treat Substance Use Disorders,

Through 2025

Table 42: AbbVie Revenue, 2017–2020

Table 43: Alkermes Revenue, 2017–2020

Table 44: AstraZeneca Revenue, 2017–2020

Table 45: Boehringer Ingelheim Revenue, 2019

Table 46: Eli Lilly Revenue, 2017–2020

Table 47: GlaxoSmithKline Revenue, 2017–2020

Table 48: H Lundbeck A/S Revenue, 2017–2020

Table 49: Johnson & Johnson Revenue, 2017–2020

Table 50: Otsuka Revenue, 2017–2020

Table 51: Pfizer Revenue, 2017–2020

Table 52: Shionogi Revenue, Through 2019



Table 53: Takeda Revenue, 2017–2020

Table 54: ACADIA Pharmaceuticals Revenue, 2017–2020

Table 55: Supernus Pharmaceuticals Revenue, 2017–2020

Table 56: Tonix Pharmaceuticals Revenues, 2017–2020

Table 57: Orexo Therapeutics Revenue, Through 2019



List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Drugs Prescribed to Treat Mental Health Disorders,

by Type of Disorder, 2019-2025

Figure 1: Prevalence of Depressive Disorders, by Region

Figure 2: Prevalence of Anxiety Disorders, by Region

Figure 3: AXS-05 Mechanism of Action

Figure 4: DSM Criteria for ADHD

Figure 5: Prevalence of ADHD Subtypes, by Age Group

Figure 6: Development Timelines of Leading ADHD Drugs

Figure 7: Prevalence of Schizophrenia Population, by Sex

Figure 8: Share of the Population with an Alcohol or Drug Use Disorder, 2016

Figure 9: People with Substance Use Disorder and Mental Health Disorder



I would like to order

Product name: Pharmaceutical Treatments for Mental Health Disorders: Global Markets

Product link: https://marketpublishers.com/r/P409F51099F0EN.html

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P409F51099F0EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970